Unlocking the opportunity of tight glycaemic control. Inhaled insulin: clinical efficacy

Diabetes, Obesity & Metabolism
Werner A Scherbaum


Numerous attempts have been made to develop novel routes of insulin delivery that are both effective and tolerable. Of all the potential non-invasive delivery options, pulmonary delivery is the most clinically viable. Early studies demonstrate that the inhaled insulin is rapidly absorbed and is closer to biological insulin than standard subcutaneous insulin (SC). To date, inhaled insulin (Exubera) has been clinically assessed in more than 3500 patients with type 1 or type 2 diabetes, some treated for more than 7 years. Several phase 3 studies of 24-week duration have demonstrated comparable glycosylated haemoglobin (HbA1c) control in patients with type 1 diabetes treated with Exubera vs. SC insulin. Similar results have also been recorded in patients with type 2 diabetes. Furthermore, Exubera has shown clinical superiority to oral agent regimens in patients with type 2 diabetes who failed to achieve their target HbA1c using lifestyle modification and oral agents. Exubera was well tolerated and treatment satisfaction was high, with Exubera being the preferred insulin therapy in all studies. The results of these trials, and others, suggest that Exubera may be a valuable tool to help a wide variety of patients with type 1 or type ...Continue Reading


Aug 1, 1982·Annals of Internal Medicine·L Rosenstock
Sep 30, 1993·The New England Journal of Medicine·Diabetes Control and Complications Trial Research GroupC Siebert
Oct 8, 1999·Diabetic Medicine : a Journal of the British Diabetic Association
Jul 18, 2002·Nature Reviews. Drug Discovery·D R Owens
Dec 25, 2003·Diabetes Care·American Diabetes Association
Jul 15, 2004·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Anthony P FurnaryStephen O Bookin
Sep 10, 2004·Clinical Pharmacokinetics·John S PattonMichael A Eldon
Jun 29, 2005·Diabetes Care·J S SkylerInhaled Insulin Phase III Type 1 Diabetes Study Group
Sep 2, 2005·Diabetes, Obesity & Metabolism·Joseph D Brain


Oct 4, 2006·Expert Opinion on Drug Metabolism & Toxicology·Chantal Mathieu
Dec 7, 2007·Best Practice & Research. Clinical Endocrinology & Metabolism·Sabine Arnolds, T Heise

Related Concepts

Inhalation of Drugs
Blood Glucose
Clinical Trials
Diabetes Mellitus
Hypoglycemic Effect

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.